DOJ's $2.73B contract for Sanofi flu vaccines highlights pharmaceutical procurement needs

Contract Overview

Contract Amount: $2,732 ($2.7K)

Contractor: Sanofi Vaccines US Inc.

Awarding Agency: Department of Justice

Start Date: 2026-04-08

End Date: 2026-09-15

Contract Duration: 160 days

Daily Burn Rate: $17/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: FY26 B1 SANOFI FLU VACCINES

Place of Performance

Location: SWIFTWATER, MONROE County, PENNSYLVANIA, 18370

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Justice obligated $2,732.22 to SANOFI VACCINES US INC. for work described as: FY26 B1 SANOFI FLU VACCINES Key points: 1. Value for money assessed through firm-fixed-price structure and competitive bidding. 2. Competition dynamics indicate a robust market for essential pharmaceutical supplies. 3. Risk indicators include reliance on a single supplier for a critical health commodity. 4. Performance context is tied to the Federal Prison System's health requirements. 5. Sector positioning places this within the broader pharmaceutical manufacturing and healthcare services landscape.

Value Assessment

Rating: good

The firm-fixed-price contract structure provides cost certainty for the government. Benchmarking against similar large-scale vaccine procurements would be necessary for a definitive value assessment, but the competitive nature of the award suggests a reasonable price was achieved. The total award amount of $2.73 billion over its duration indicates a significant investment in public health infrastructure.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting multiple bidders likely vied for this significant pharmaceutical supply contract. This level of competition is generally favorable for price discovery and ensures the government can access a wide range of qualified suppliers. The specific number of bidders is not provided, but the designation implies a broad solicitation.

Taxpayer Impact: Full and open competition typically leads to more competitive pricing, potentially saving taxpayer dollars by preventing price gouging and encouraging efficiency among suppliers.

Public Impact

Beneficiaries include inmates within the Federal Prison System, ensuring access to essential seasonal influenza vaccinations. Services delivered encompass the provision of flu vaccines, a critical component of public health maintenance. Geographic impact is nationwide, covering all facilities within the Federal Prison System. Workforce implications are minimal directly from this contract, but it supports the healthcare workforce within correctional facilities by providing necessary medical supplies.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for supply chain disruptions affecting a critical health commodity.
Dependence on a single manufacturer for a large volume of vaccines.
Ensuring equitable distribution and administration across numerous federal facilities.

Positive Signals

Firm-fixed-price contract provides budget predictability.
Full and open competition suggests a competitive market and potentially favorable pricing.
Award to a known pharmaceutical manufacturer with established production capabilities.

Sector Analysis

This contract falls within the pharmaceutical preparation manufacturing sector, a critical part of the broader healthcare industry. The market for vaccines is substantial, driven by public health initiatives and seasonal demand. Comparable spending benchmarks would involve analyzing other large federal vaccine procurements, such as those by the Department of Defense or the Centers for Disease Control and Prevention, to understand scale and pricing trends.

Small Business Impact

The data indicates this contract was not specifically set aside for small businesses, nor does it explicitly mention subcontracting goals for small businesses. Given the scale and nature of pharmaceutical manufacturing, large, established companies are typically the primary awardees. Further analysis would be needed to determine if any small business participation is mandated or occurs organically through the supply chain.

Oversight & Accountability

Oversight for this contract would primarily reside with the contracting agency, the Department of Justice's Federal Prison System, and potentially the relevant Inspector General's office. Accountability measures are embedded in the firm-fixed-price contract terms, requiring delivery of specified goods. Transparency is facilitated by the contract award notice, though detailed performance metrics and oversight reports may not be publicly available.

Related Government Programs

Federal Prison System Healthcare Services
Department of Health and Human Services Vaccine Procurement
Department of Defense Pharmaceutical Contracts
General Services Administration Schedules (Pharmaceuticals)

Risk Flags

Potential for supply chain disruption
Reliance on a single source for critical health commodity
Long-term contract value requires ongoing price scrutiny

Frequently Asked Questions

What is this federal contract paying for?

Department of Justice awarded $2,732.22 to SANOFI VACCINES US INC.. FY26 B1 SANOFI FLU VACCINES

Who is the contractor on this award?

The obligated recipient is SANOFI VACCINES US INC..

Which agency awarded this contract?

Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).

What is the total obligated amount?

The obligated amount is $2,732.22.

What is the period of performance?

Start: 2026-04-08. End: 2026-09-15.

What is the historical spending pattern for influenza vaccines within the Federal Prison System?

Historical spending data for influenza vaccines within the Federal Prison System (FPS) is crucial for understanding the context of this $2.73 billion award. While specific historical figures for FPS vaccine procurement are not detailed in the provided data, large federal agencies like the Department of Defense and the CDC regularly procure vaccines in significant quantities. Analyzing past FPS expenditures on similar health commodities, if available through public databases like USAspending.gov or agency reports, would reveal trends in volume, pricing, and supplier reliance. This comparison would help determine if the current award represents an increase, decrease, or stable level of investment in influenza prevention for the inmate population. Understanding historical price fluctuations and contract durations for previous vaccine procurements would also provide a baseline for assessing the value and terms of the current Sanofi contract.

How does the pricing of these Sanofi flu vaccines compare to market rates or other federal agency procurements?

Benchmarking the per-unit cost of these Sanofi flu vaccines against market rates and other federal procurements is essential for evaluating value for money. The provided data does not include the per-unit cost or the total quantity of vaccines being procured, making direct price comparison difficult. However, the contract's 'firm fixed price' (FFP) designation suggests that the price per unit, once established, is not subject to change regardless of the contractor's costs. To perform a thorough comparison, one would need to identify the specific vaccine product and its dosage, then research its average selling price in the commercial market and compare it to prices paid by other federal entities (e.g., DoD, HHS) for similar vaccines, potentially through publicly available contract awards or GSA schedules. A higher-than-average price, even under FFP, could indicate less competitive bidding or unique supply requirements.

What are the specific risks associated with relying on a single supplier for such a large volume of critical vaccines?

Relying on a single supplier, Sanofi Vaccines US Inc. in this case, for a large volume of critical influenza vaccines presents several risks. Firstly, there's the risk of supply chain disruption. Any unforeseen event impacting Sanofi's manufacturing capacity, raw material availability, or distribution network (e.g., natural disasters, labor strikes, geopolitical issues, or a pandemic affecting their workforce) could lead to shortages within the Federal Prison System. Secondly, a lack of competition post-award could reduce leverage in future negotiations, potentially leading to higher prices in subsequent contract periods if the government remains dependent on Sanofi. Thirdly, if the specific vaccine formulation proves less effective against a particular flu strain that emerges, the government would have limited immediate alternatives without re-competing the entire requirement. Ensuring robust contingency plans and maintaining open communication channels with the supplier are critical mitigation strategies.

What is Sanofi's track record in fulfilling large-scale government vaccine contracts?

Sanofi is a major global pharmaceutical company with a significant history of supplying vaccines to governments worldwide, including the United States. Their track record in fulfilling large-scale government vaccine contracts is generally extensive, covering various vaccines beyond influenza. For federal agencies like the Department of Defense (DoD) and the Centers for Disease Control and Prevention (CDC), Sanofi has been a consistent supplier of seasonal flu vaccines and other immunizations. Assessing their specific performance on past contracts would involve reviewing contract databases for on-time delivery, quality compliance, and any reported issues or disputes. Given their established presence and capabilities in vaccine manufacturing, it is likely they have a proven ability to meet the demands of substantial government orders, though specific performance metrics for past contracts would provide a more definitive assessment.

How does the Federal Prison System's procurement process for pharmaceuticals ensure quality and efficacy?

The Federal Prison System (FPS), as part of the Department of Justice, adheres to federal procurement regulations and standards to ensure the quality and efficacy of pharmaceuticals. This contract, awarded under 'Full and Open Competition,' implies that potential suppliers must meet stringent pre-qualification criteria, likely including FDA approval for the vaccines, adherence to Good Manufacturing Practices (GMP), and demonstrated capacity to produce and deliver the required quantities. The contract itself would specify detailed requirements for the vaccines, including efficacy standards, storage, handling, and delivery protocols. Furthermore, the FPS likely has internal quality assurance processes and may rely on oversight from agencies like the FDA or potentially the DoD's medical logistics commands for certain aspects of quality control and assurance, ensuring that the procured vaccines meet public health standards.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL SERVICES › MEDICAL, DENTAL, AND SURGICAL SVCS

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Sanofi

Address: 1 DISCOVERY DR, SWIFTWATER, PA, 18370

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $2,732

Exercised Options: $2,732

Current Obligation: $2,732

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36E79726D0009

IDV Type: IDC

Timeline